Neuropharmacology & Neurotherapeutics
Fingolimod, an S1P receptor modulator, has an immunosuppressant effect in patients with multiple sclerosis. The neuroprotective effect of fingolimod on relapsing-remitting multiple sclerosis may be due to its modulatory effect on oligodendroglial cells and astrocytes as well as its direct effect on cortical neurons. Adverse events during clinical trials have included bradycardia and atrioventricular block, respiratory and herpesvirus infections, increased liver enzyme levels, hypertension, and macular edema.
Jul. 27, 2021